Ascochlorin, an isoprenoid antibiotic, induces G1 arrest via downregulation of c-Myc in a p53-independent manner

Biochemical and Biophysical Research Communications

Volumn 398, Issue 1, 2010, Pages 68-73

  Jeong, Ji Hak ^a   Chang, Young Chae ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Ascochlorin; C Myc; G1 arrest; P21WAF1 CIP1; P53

Indexed keywords

ANTIBIOTIC AGENT; ASCOCHLORIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; ISOPRENOID; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ALKENES; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; G1 PHASE; HUMANS; PHENOLS; PROTO-ONCOGENE PROTEINS C-MYC; TERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954762032     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.037     Document Type: Article

References (25)

1. Meek D.W. Tumour suppression by p53: a role for the DNA damage response?. Nat. Rev. Cancer 2009, 9:714-723.
2. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
3. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., Cleveland J.L., Tansey W.P., Lowe S.W. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436:807-811.
4. Sasaki H., Hosokawa T., Sawada M., Ando K. Isolation and structure of ascofuranone and ascofranol, antibiotics with hypolipidemic activity. J. Antibiot. (Tokyo) 1973, 26:676-680.
5. G. Tamura, S. Suzuki, A. Takatsuki, K. Ando, K. Arima, Ascochlorin, a new antibiotic, found by the paper-disc agar-diffusion method. I. Isolation, biological and chemical properties of ascochlorin (Studies on antiviral and antitumor antibiotics. I). J. Antibiot. (Tokyo) 21 (1968) 539-544.
6. Sawada M., Hosokawa T., Okutomi T., Ando K. Hypolipidemic property of ascofuranone. J. Antibiot. (Tokyo) 1973, 26:681-686.
7. Hosokawa T., Okutomi T., Sawada M., Ando K., Tamura G. Unusual concentration of urine and prevention of polydipsia by fungal prenylphenols in DOCA hypertensive rats. Eur. J. Pharmacol. 1981, 69:429-438.
8. Hosokawa T., Ando K., Tamura G. An ascochlorin derivative, AS-6, reduces insulin resistance in the genetically obese diabetic mouse, db/db. Diabetes 1985, 34:267-274.
9. Magae J., Suzuki S., Nagai K., Yamasaki M., Ando K., Tamura G. In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system. Cancer Res. 1986, 46:1073-1078.
10. Magae J., Hayasaki J., Matsuda Y., Hotta M., Hosokawa T., Suzuki S., Nagai K., Ando K., Tamura G. Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes. J. Antibiot. (Tokyo) 1988, 41:959-965.
11. Magae J., Hosokawa T., Ando K., Nagai K., Tamura G. Antitumor protective property of an isoprenoid antibiotic, ascofuranone. J. Antibiot. (Tokyo) 1982, 35:1547-1552.
12. Jeong J.H., Nakajima H., Magae J., Furukawa C., Taki K., Otsuka K., Tomita M., Lee I.S., Kim C.H., Chang H.W., Min K.S., Park K.K., Chang Y.C. Ascochlorin activates p53 in a manner distinct from DNA damaging agents. Int. J. Cancer 2009, 124:2797-2803.
13. Li H., Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem. Biophys. Res. Commun. 2004, 324:860-867.
14. Datto M.B., Yu Y., Wang X.F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 1995, 270:28623-28628.
15. Chang Y.C., Illenye S., Heintz N.H. Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene. Mol. Cell Biol. 2001, 21:1121-1131.
16. Herold S., Wanzel M., Beuger V., Frohme C., Beul D., Hillukkala T., Syvaoja J., Saluz H.P., Haenel F., Eilers M. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 2002, 10:509-521.
17. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
18. Michod D., Widmann C. DNA-damage sensitizers: potential new therapeutical tools to improve chemotherapy. Crit. Rev. Oncol. Hematol. 2007, 63:160-171.
19. Seoane J., Le H.V., Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-734.
20. Dang C.V. C-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell Biol. 1999, 19:1-11.
21. Gartel A.L., Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp. Cell Res. 2003, 283:17-21.
22. Tapias A., Ciudad C.J., Roninson I.B., Noe V. Regulation of Sp1 by cell cycle related proteins. Cell Cycle 2008, 7:2856-2867.
23. Donjerkovic D., Scott D.W. Regulation of the G1 phase of the mammalian cell cycle. Cell. Res. 2000, 10:1-16.
24. Giacinti C., Giordano A. RB and cell cycle progression. Oncogene 2006, 25:5220-5227.
25. DeGregori J., Johnson D.G. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr. Mol. Med. 2006, 6:739-748.